Beta Bionics (BBNX) grants 91,520 stock options to CPO

Rhea-AI Filing Summary

Beta Bionics, Inc. reported that Chief Product Officer Mike Mensinger received a grant of employee stock options covering 91,520 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036. According to the disclosure, these options vest in 36 equal monthly installments starting on March 1, 2026, meaning the award vests gradually over three years as continued service is provided.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mensinger Mike

Role Chief Product Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	91,520	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 91,520 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		91,520		(1)	02/26/2036	Common Stock	91,520	$0	91,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Remarks:

The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beta Bionics (BBNX) report for Mike Mensinger?

Beta Bionics reported that Chief Product Officer Mike Mensinger received a grant of 91,520 employee stock options. These options allow him to buy common shares at a fixed price if they vest and are exercised over time.

How many stock options were granted to the Beta Bionics CPO in this Form 4/A?

The Chief Product Officer was granted 91,520 employee stock options. Each option is tied to one share of common stock, giving significant potential equity exposure if the options vest and are exercised in the future.

What is the exercise price of the options granted to the Beta Bionics CPO?

The options have an exercise price of $12.63 per share. This is the price at which the holder can buy common stock if the options vest and are exercised before they expire in 2036.

When do the newly granted Beta Bionics options start vesting and over what period?

The options begin vesting on March 1, 2026, in 36 equal monthly installments. This structure spreads vesting over three years, encouraging continued service during that period for the Chief Product Officer.

When do the stock options granted to the Beta Bionics CPO expire?

The employee stock options expire on February 26, 2036. If they are not exercised by that date, they lapse and can no longer be used to purchase Beta Bionics common stock at the $12.63 exercise price.

Is this Beta Bionics Form 4/A transaction a purchase or a grant of options?

The transaction is a grant of options, classified as a grant, award, or other acquisition. It reflects compensation in the form of stock options rather than an open-market purchase or sale of existing common shares.